Analyst Price Targets — ALT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 22, 2026 10:30 am | Thomas Smith | Leerink Partners | $10.00 | $3.01 | TheFly | Altimmune initiated with an Outperform at Leerink |
| April 24, 2026 9:10 am | Corinne Johnson | Goldman Sachs | $2.50 | $2.89 | TheFly | Altimmune upgraded to Neutral from Sell at Goldman Sachs |
| January 27, 2026 9:11 pm | — | Barclays | $20.00 | $6.18 | TheFly | Altimmune initiated with an Overweight at Barclays |
| April 2, 2024 6:42 am | Patrick Trucchio | H.C. Wainwright | $12.00 | $10.23 | StreetInsider | Altimmune (ALT) PT Lowered to $12 at H.C. Wainwright following Q4 report |
| December 1, 2022 5:36 am | — | Goldman Sachs | $20.00 | $9.95 | Benzinga | Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20 |
| November 11, 2022 8:29 am | — | JMP Securities | $26.00 | $11.12 | Benzinga | JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $26 |
| August 31, 2022 11:00 am | — | Jefferies | $35.00 | $22.08 | Benzinga | Jefferies Maintains Buy on Altimmune, Raises Price Target to $35 |
| August 30, 2022 8:40 pm | Yasmeen Rahimi | Piper Sandler | $25.00 | $18.94 | TheFly | Altimmune management confident on NAFLD Phase 1b study, says Piper Sandler |
| August 17, 2022 6:36 am | — | H.C. Wainwright | $50.00 | $17.66 | Benzinga | HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $50 |
Latest News for ALT
Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed statistically significant MASH resolution and fibrosis improvement, but competition from semaglutide, resmetirom, and others remains intense. ALT's near-term catalyst is the Phase 2 AUD data, with potential for partnership if results demonstrate…
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALT.
U.S. House Trading
No House trades found for ALT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.